论文部分内容阅读
目的观察预混门冬胰岛素30(诺和锐30)治疗2型糖尿病(T2DM)的疗效。方法将104例口服降糖药血糖控制不佳的T2DM患者随机分为诺和锐30组53例和预混人胰岛素30R(诺和灵30R)组51例。每天早晚餐前皮下注射诺和锐30及诺和灵30R,治疗12周后比较2组空腹血糖(FPG)、餐后2h血糖(2h PG)、糖化血红蛋白(Hb A1c)和低血糖发生率。结果治疗前2组FPG、2h PG、Hb A1c水平差异无统计学意义(P>0.05)。治疗后2组FPG、2h PG、Hb A1c水平均低于治疗前,且诺和锐30组早餐、晚餐后2h PG和Hb A1c水平低于诺和灵30R组,差异均有统计学意义(P<0.05)。2组治疗后空腹血糖、中餐后2h PG水平差异均无统计学意义(P>0.05)。诺和锐30组低血糖、严重低血糖发生率均低于诺和灵30R组,差异有统计学意义(P<0.05)。结论诺和锐30治疗T2DM效果显著,且有良好的安全性,优于诺和灵30R,值得临床推广应用。
Objective To observe the effect of prefixed aspart insulin 30 (Novo-Rui 30) on type 2 diabetes mellitus (T2DM). Methods Totally 104 T2DM patients with poor glycemic control on oral hypoglycemic agents were randomly divided into Novo-Rui 30 group (n = 53) and pre-mixed insulin 30R (norepinephrine 30R) group. Novokor 30 and Novolin 30R were injected subcutaneously daily before and after meals. The fasting blood glucose (FPG), 2h PG, Hb A1c and hypoglycemia were compared between the two groups after 12 weeks of treatment. Results There was no significant difference in FPG, 2h PG and Hb A1c levels between the two groups before treatment (P> 0.05). After treatment, the levels of FPG, 2h PG and Hb A1c in two groups were lower than those before treatment, and the levels of PG and Hb A1c in Novo-Rui 30 group were lower than those in Norvuling 30R group at breakfast 2h, and the differences were statistically significant (P <0.05). There was no significant difference in fasting blood glucose and PG level after 2 hours of treatment between the two groups (P> 0.05). The incidence of hypoglycemia and severe hypoglycemia in Novo-Rui-30 group was significantly lower than that in No-Retino 30R group (P <0.05). Conclusions Nuo-Rui-Rui 30 treatment of T2DM effect was significant, and good safety, superior to Norolt 30R, worthy of clinical application.